Home > Formulary : Adult > Recent Decisions > 2023 >
Decisions 17th October 2023
New Drug Requests:
Approved
Droperidol (TLS Red)
- management of acute behavioural disturbance in the Emergency Department. Alternative to ketamine.
Bijuve® (1mg estradiol / 100mg micronised progesterone) (TLS Green)
- HRT for postmenopausal women
- Second line treatment option and alternative to Femoston-Conti where first line options have not been tolerated / are not suitable.
Aklief® (trifarotene cream 50micrograms/g) (TLS Green)
- treatment of acne
Other decisions and discussions:
SCP Review Work:
- Oral testosterone for male hypogonadism to be removed from the formulary as no longer used.
- Danazol for hereditary angiodema - change TLS to Amber Specialist Initiated.
- Rivaroxaban with anti-platelets in line with NICE TA 335 and TA 607 - change TLS to Amber Specialist Recommended and remove SCPs once a guideline to support use of concomitant DOAC and anti-platelets is developed.
ADHD medicines shortage discussed.
Adex gel emollient - not approved for treatment of eczema, psoriasis and dermatitis.
Doublebase Once emollient - not approved for treatment of eczema, psoriasis and dermatitis.